Abstract TP134: Association of Diabetes, Glycemic Control, and Macroalbuminuria with Ischemic and Bleeding Risk During Antithrombotic Therapy

Background: Diabetes mellitus induces a prothrombotic state through mechanisms including platelet activation, leading to reduced responsiveness to antithrombotic therapy. However, the clinical consequences of diabetes, glycemic control, and diabetic nephropathy on the risk of ischemic and bleeding events under antithrombotic therapy have not been fully investigated. Methods: This was a prospective, multicenter observational study, enrolling patients receiving oral antiplatelets or anticoagulants. Baseline brain MRI was performed to assess small vessel disease (SVD): white matter hyperintensity, cerebral microbleed, lacune, enlarged perivascular space, with central reading. The SVD burden was defined as SVD score >2 (range, 0–4). Cox regression models were used to evaluate the associations of diabetes, hemoglobin A1c (HbA1c) categories (